SHR-A1403 Antibody
SHR-A1403 Antibody is an anti-c-Met monoclonal antibody. SHR-A1403 Antibody down-regulates phosphorylated c-Met, Akt, ERK, weakens intracellular signal cascades, and mediates antibody-c-Met complex endocytosis. SHR-A1403 Antibody can be used for the research of c-met-overexpressing cancers and pancreatic ductal adenocarcinoma.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vitro
SHR-A1403 Antibody (SHR-A1403 mAb) binds with high affinity to human and cynomolgus monkey c-Met (Kd values of 1.58 × 10-8 M and 2.84 × 10-8 M, respectively) and does not bind mouse c-Met[1].
SHR-A1403 Antibody has low to no binding affinity to human Fc receptors and complement C1q, with measurable low affinity only for FcRn, FcγR I/CD64, and FcγR III/CD16[1].
SHR-A1403 Antibody (72 h) minimally inhibits proliferation of NCI-H1993, NCI-H441, A549, MKN-45, NCI-N87, Hs578T, PC-3, Caki-1, and HCCLM3 human cancer cell lines, with IC50 values greater than 5000 ng/mL[1].
SHR-A1403 Antibody (1 h) binds to human gastric cancer MKN-45 cells in a dose dependent manner[1].
SHR-A1403 Antibody (10-10000 ng/mL; 24 h) dose-dependently inhibits c-Met downstream signaling in human gastric cancer MKN-45 cells, reducing phosphorylated c-Met, Akt, and ERK levels[1].
SHR-A1403 Antibody (10 μg/mL; 1 h) is time-dependently internalized into human gastric cancer MKN-45 cells, reaching an endocytosis rate of ~30% after 3 h of incubation at 37 °C[1].
SHR-A1403 Antibody (1 μg/mL; 23 h) translocates to lysosomes in human gastric cancer MKN-45 cells[1].
SHR-A1403 Antibody (4 h) exhibits no detectable ADCC activity against human gastric cancer MKN-45 cells[1].
SHR-A1403 Antibody (15 min) exhibits low CDC activity against human gastric cancer MKN-45 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:human gastric cancer MKN-45 cells
-
Concentration:10; 100; 1000; 10000 ng/mL
-
Incubation Time:24 h
-
Result:Dose-dependently downregulated levels of phosphorylated c-Met, phosphorylated Akt, and phosphorylated ERK.
Showed equivalent potency to the ADC form of SHR-A1403 at the same concentrations.
Decreased total c-Met levels with increasing concentration.
In Vivo
SHR-A1403 Antibody (10 mg/kg; i.v.; on days 0, 3, 7, 10, 14, 17) exhibits minor anti-tumor efficacy in NCI-H1993 xenograft tumors in BALB/cA-nude mice, achieving a terminal TGI of 42%[1].
SHR-A1403 Antibody (10 mg/kg; i.v.; single dose on day 0) exhibits moderate anti-tumor efficacy in MKN-45 xenograft tumors in BALB/cA-nude mice, achieving a terminal TGI of 45%[1].
SHR-A1403 Antibody (10 mg/kg; i.v.; single dose) shows minimal anti-tumour activity in BALB/c nude mice bearing Aspc-1 pancreatic ductal adenocarcinoma xenografts[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/cA-nude mice (male, 6-7 weeks old) implanted with HCCLM3 tumor tissue[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; twice-weekly; on days 0, 3, 7, 10, 14, 17
-
Result:Achieved a terminal tumor growth inhibition (TGI) of 36%.
Reached a mean tumor volume of 1159 mm3 by day 17 post-treatment.
Confirmed the PDX tumor had high c-Met expression (IHC score 3+).
Caused no significant body weight loss.
-
Animal Model:BALB/cA-nude mice (male, 6-7 weeks old) implanted with NCI-H1993 tumor tissue[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; twice-weekly; on days 0, 3, 7, 10, 14, 17
-
Result:Achieved a terminal tumor growth inhibition (TGI) of 42%.
Caused no significant body weight loss.
-
Animal Model:BALB/cA-nude (male, 6-7 weeks old) implanted with MKN-45 tumor tissue[1]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose on day 0
-
Result:Achieved a terminal tumor growth inhibition (TGI) of 45%.
Caused no significant body weight loss.
-
Animal Model:BALB/c nude mice (female, 4-6 weeks old) subcutaneously injected with spc-1 cells[2]
-
Dosage:10 mg/kg
-
Administration:i.v.; single dose
-
Result:Showed a less pronounced reduction in subcutaneous tumour volume than SHR-A1403 (the ADC).
Exhibited no significant difference in tumour weight compared to control group.
Exhibited no significant difference in body weight compared to control group over the 21-day observation period.
Gene ID
Accession
Target
HGFR/c-Met
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[1]. Yang CY, et al. SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models. Acta Pharmacol Sin. 2019 Jul;40(7):971-979. [Content Brief]
[2]. Jin Y, et al. A Novel c-MET-Targeting Antibody-Drug Conjugate for Pancreatic Cancer. Front Oncol. 2021 Mar 17;11:634881. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
SHR-A1403 Antibody Related Classifications
HY-P992464 Related Classifications
Powered by Bioz